JAKARTA – PT Lippo Karawaci Tbk ("LPKR" or "Company"), Indonesia’s leading real estate and healthcare platform based on total assets and revenue, today released its unaudited financial statements for the first nine months of 2022. In 3Q22, the Company achieved revenue growth of 7.3% QoQ to IDR 3.7tn. Gross profit and EBITDA also increased by 8.3% QoQ to IDR 1.6tn, and 3.8% QoQ to IDR 704bn respectively. The increase was driven by the continued business performance of the healthcare and lifestyle segments. NPAT decreased by 12.9% QoQ to -IDR 720bn mainly due to higher tax and other expenses.
* Underlying NPAT include interest, tax, depreciation and the rental expense equivalent component from the PSAK 73 leasing calculation
** PSAK 73 adjustment only includes the non-cash component of PSAK 73 leasing calculation (i.e., net of the rental equivalent)
The Company reported a 7.0% YoY decrease in 9M22 revenue to IDR 10.5tn compared to Normalized 9M21 due to comparatively lower revenue from the real estate and healthcare businesses from last year’s peak performance. This decrease was partially offset by the stronger performance from the lifestyle business.
In 9M22, the Company increased its Underlying NPAT by 6.1% YoY to -IDR 769bn, while NPAT in 9M22 decreased by 65.9% YoY to -IDR 1.93tn largely due to unrealized FX loss from the USD/IDR appreciation. The Company has a USD/IDR hedge position of Rp15,000 to Rp17,500 for most of its FX exposure to minimize further impacts.
*Normalized figures adjusted to exclude the effect of LMIRT consolidation and Puri Mall Sale in 9M21
** Underlying NPAT include interest, tax, depreciation and the rental expense equivalent component from the PSAK 73 leasing calculation
*** PSAK 73 adjustment only includes the non-cash component of PSAK 73 leasing calculation (i.e., net of the rental equivalent)
The Company’s cash flow from business operations has improved substantially by 99.1% YoY to a small negative of -IDR 12bn compared to -IDR 1.3tn from the same period last year after excluding the IDR 530bn placement in restricted funds for back-to-back loan purposes.
Decreased cash from investing activities in 9M22 by IDR 3.2tn was mainly due to the cash inflow from sale of Puri Mall in 9M21, while in 9M22 there was a purchase of land and building of Siloam Surabaya by IDR 430bn by SILO, and the acquisition of SILO shares done by the Company. IDR
1.17tn had been deployed for investment to support future growth and produce sustainable future cash flows.
Real Estate: Pushing ahead with new launches and unique products, while speeding up project handover in 4Q22
Real estate’s 3Q22 revenue declined by 8.6% QoQ to IDR 920bn, as there were more unit handovers in 2Q22 due to the handover schedule. Gross profit decreased by 24.5% QoQ to IDR
375bn due to changes in product mix, whereby there were fewer landed residential handovers compared to apartment handovers in 3Q22. The difference in GPM between apartment and landed house was in the range of 25% to 30%. We expect the GPM to improve next quarter, in line with the handover activity of several landed projects launched in 2021, including Cendana Parc.
In terms of marketing sales performance, the company achieved IDR 3.5tn in 9M22, decreased by 9% YoY as the impact from rising inflation during this year has starting to taken place.
To meet Management’s FY22 target of IDR 5.2tn in marketing sales, the Company will launch additional clusters of landed residential houses in 4Q22, as well as a low-rise project in Lippo Cikarang and a new apartment project in Lippo Village.
Healthcare: SILO’s growth speeds up as it normalizes from Covid-19 environment
The Company’s healthcare business is operating under Company’s subsidiary, PT Siloam International Hospitals Tbk (“SILO”). In 9M22, SILO was a major contributor to the Company’s total revenue by 65.7%.
SILO continued to improve its performance in 3Q22, with 15.2% QoQ revenue increase to IDR 2.5tn, gross profit increase by 31.4% QoQ to IDR 1.1tn and EBITDA increase by 50.4% QoQ to IDR 584bn. These achievements further confirmed SILO’s strong trajectory to recovery from pandemic impact.
In terms of SILO’s operational metrics, its operational performance continued on its steep upwards growth trajectory in 3Q22. The Inpatient Days and Outpatient Visits were the highest volumes seen in 10 quarters.
Inpatient Days in 9M22 increased by 8.3% to 587,617, compared with 542,772 in 9M21. In 9M22 Siloam has treated more than 2.2 million Outpatients, an increase of 32.2% compared with 9M21. SILO’s 3Q22 Inpatient Days of 219,689 was 16.8% higher than Inpatient Days in 2Q22. SILO recorded 841,607 Outpatient visits in 3Q22, an increase of 17.9% compared with 2Q22. COVID patient volumes were insignificant, accounting for only 1% of patient days. Patient Volume growth is not concentrated but come from wide range of specialties. SILO high value Centres of Excellences such as Oncology, Cardiology, Neurology and Urology continues to grow beyond pre-covid while medical cases are returning, paving for sustainable growth.
SILO continued to invest in its digital patient platform capabilities and engagement to further improve the patients’ experience. These digital channels include MySiloam App, SILO’s website, dedicated live chat and dedicated WhatsApp number. As the popularity of SILO’s digital channels increased, the number of digitally acquired patients has also increased. As of 9M22, these digital channels contributed about 18% of total outpatients. SILO’s Homecare business continued to grow volumes even after the pandemic. As of 9M22, the Company’s Homecare business has provided more than 50 thousand services to more than 21 thousand patients.
Lifestyle: Continues recovery of mall’s traffic and hotel occupancy rate
The Company’s lifestyle segment primarily consists of its mall and hotel business. In 3Q22, the Company maintained its performance with an increase in revenue of 1.7% QoQ to IDR 289bn. Opex decreased by 26.0% QoQ, resulting in a significant increase in EBITDA of 56.6% QoQ to IDR 87bn.
SILO continued to invest in its digital patient platform capabilities and engagement to further improve the patients’ experience. These digital channels include MySiloam App, SILO’s website, dedicated live chat and dedicated WhatsApp number. As the popularity of SILO’s digital channels increased, the number of digitally acquired patients has also increased. As of 9M22, these digital channels contributed about 18% of total outpatients. SILO’s Homecare business continued to grow volumes even after the pandemic. As of 9M22, the Company’s Homecare business has provided more than 50 thousand services to more than 21 thousand patients.
Lifestyle: Continues recovery of mall’s traffic and hotel occupancy rate
The Company’s lifestyle segment primarily consists of its mall and hotel business. In 3Q22, the Company maintained its performance with an increase in revenue of 1.7% QoQ to IDR 289bn. Opex decreased by 26.0% QoQ, resulting in a significant increase in EBITDA of 56.6% QoQ to IDR 87bn.
By normalizing LMIRT’s business impact to 9M21 book, the lifestyle segment’s revenue in 9M22 increased significantly by 31.5% YoY to IDR 822bn. This was due to the improvement in hotel
occupancy rate and room rate, as well as increased mall traffic, further reflecting the steady recovery of the industry coming out of the pandemic.
The average hotel room rate in 3Q22 increased by 9.7% QoQ to IDR 544,291. Average occupancy rate also increased, reaching 69% in 3Q22. The average mall’s footfall traffic in 3Q22 saw a slight decrease QoQ compared to the high season in 2Q22, but overall, a 38.9% YoY improvement in 9M22 compared to 9M21.
Recent Events
• On 24 September 2022, LPCK launched the first Cendana Homes series, a first-home owner landed residential clusters, in Lippo Cikarang named Cendana Spark. Successfully sold 151 units as of 30 September 2022, with total sales of IDR 142bn.
• On 1 October 2022, LPKR launched another Cendana Homes series in a new area in Lippo Village named Cendana Botanic, successfully sold 117 units.
• As part of the Company’s strategy to mitigate the risk of rising inflation, which has an impact on purchasing power, the Company has introduced several new products that are unique yet affordable. This includes a new low-rise project targeting millennials and Gen-Z named Newville in Lippo Cikarang, with price point starting from IDR 279mn per unit, as well as a new apartment project in Lippo Village named Urbn-X, which also has an affordable price point starting from IDR 403mn per unit.
CEO of LPKR, John Riady stated, “We have been able to maintain our overall business performance in 9M22 despite the challenging macroeconomic environment, which has put some pressure on our real estate business. Nevertheless, our healthcare and lifestyle segments have continued on their strong growth trajectory, which has allowed us to reap recurring revenue that supports our overall performance. Going into the last quarter this year, we will focus on completing project handovers on time and capturing more demand through new launches, while maintaining the good operational performance of our healthcare and lifestyle business.”
About Lippo Karawaci (“LPKR”) (www.lippokarawaci.co.id)
Listed on the Indonesia Stock Exchange, Lippo Karawaci (“LPKR”) is Indonesia’s leading real estate and healthcare platform, with a presence in 44 cities across Indonesia and total assets of US$3.6 billion at 31 December 2021. Our core business comprises urban residential developments, lifestyle malls and healthcare. We are also actively involved in integrated developments, hospitality, township development and management, as well as asset management services.
As a leading real estate developer and township operator with 1,332 ha of landbank ready for development, LPKR develops and manages urban developments primarily in Java and Sulawesi, including at our flagship township Lippo Village in Tangerang. Through LPKR’s two publicly listed subsidiaries, PT Lippo Cikarang Tbk and PT Gowa Makassar Tourism Development Tbk, of which we own 84.0% and 62.7% respectively, we also develop and manage the townships of Lippo Cikarang in Bekasi and Tanjung Bunga in Makassar.
In addition, LPKR owns 57.9% of PT Siloam International Hospitals Tbk, Indonesia’s leading private hospital network, with 41 hospitals in 30 cities nationwide. Aside from healthcare, we manage 59 malls across Indonesia, and hold a 47.0% stake in Lippo Malls Indonesia Retail Trust, a Singapore-listed REIT with SGD1.81 billion of assets under management as of December 31, 2021. We also operate 10 hotels under the Aryaduta brand, including a country club and golf course.
For more information, please contact:
Investor Relations:
Dr. Randi Bayu Prathama
Head of Investor Relations
Randi.Prathama@lippokarawaci.co.id
Office: +62811225873
Corporate Communications:
Nuke Prabandari
Head of Corporate Communications
Nuke.Prabandari@lippokarawaci.co.id
Office: +622125569000
This press release has been prepared by PT Lippo Karawaci Tbk (“LPKR”) and is circulated for the purpose of general information only. All opinions and estimations included in this release constitute our judgment as of this date and are subject to change without prior notice. LPKR disclaims any responsibility or liability whatsoever arising which may be brought against or suffered by any person as a result of reliance upon the whole or any part of the contents of this press release and neither LPKR nor any of its affiliated companies and their respective employees and agents accepts liability for any errors, omissions, negligent or otherwise, in this press release and any inaccuracy herein or omission here from which might otherwise arise.
Forward-Looking Statements
Certain statements in this release are or may be forward- looking statements. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature, forward-looking statements involve a number of risks and uncertainties that could cause actual events or results to differ materially from those described in this release.